Author

Hiroki Izumi

Moores Cancer Center, University of California San Diego, La Jolla, California. 1ORCID 0000-0002-9566-4859Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Ayush KishoreiD· 1 shared J. Silvio GutkindiD· 1 shared Keiichi KoshizukaiD· 1 shared Kuniaki SatoiD· 1 shared Kyle FordiD· 1 shared Michael M. AllevatoiD· 1 shared Nadia ArangiD· 1 shared Prashant MaliiD· 1 shared

Activity by Year

2023-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ayush KishoreORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivAug 7, 2023

A kinome-wide synthetic lethal CRISPR/Cas9 screen reveals that mTOR inhibition prevents adaptive resistance to CDK4/CDK6 blockade in HNSCC

Yusuke Goto, Keiichi Koshizuka, Toshinori Ando…·J. Silvio Gutkind

This study identifies mTOR inhibition as a way to prevent adaptive resistance to CDK4/6 blockade in HNSCC by targeting cell cycle pathways.

DOI 10.1158/2767-9764.crc-24-0247

humanexperimental assay

𝕏 PostBluesky